Daniel has made over 1 trades of the Catalyst Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Daniel sold 5,781 units of CPRX stock worth $110,764 on 9 August 2016.
The largest trade Daniel's ever made was selling 5,781 units of Catalyst Pharmaceuticals Inc stock on 9 August 2016 worth over $110,764. On average, Daniel trades about 1,156 units every 0 days since 2016. As of 9 August 2016 Daniel still owns at least 1 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Daniel Brennan stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 1250, , CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany a Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: